Evidence analysisNovember 17, 2026Health & Science

Human medicines European public assessment report (EPAR): Talmanco (previously Tadalafil Generics), tadalafil, Date of authorisation: 09/01/2017, Revision: 12, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

What is established

Talmanco is a pharmaceutical medication authorized for use in the European Union for the treatment of adults with pulmonary arterial hypertension (PAH). PAH is characterized by abnormally high blood pressure in the arteries of the lungs, which limits oxygen intake and reduces exercise capacity.

The active substance in Talmanco is tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor. By blocking the PDE5 enzyme found in lung blood vessels, tadalafil increases levels of cyclic guanosine monophosphate (cGMP), causing vasodilation, reducing pulmonary blood pressure, and improving symptoms and physical capacity in PAH patients.

Talmanco is classified as a generic medicine, meaning it contains the same active ingredient and is considered bioequivalent to the reference medicine Adcirca, which has an established clinical profile. This bioequivalence suggests it has the same efficacy and safety profile as Adcirca.

What the source claims

  • The European Medicines Agency (EMA) assessed Talmanco and recommended its authorization in the European Union based on bioequivalence studies and quality data provided by the manufacturer.
  • The recommended dosage is 40 mg per day, administered as two 20 mg tablets. Lower doses are advised for patients with mild to moderate kidney or liver impairment, and it is not recommended for patients with severe impairment.
  • The EMA’s Committee for Medicinal Products for Human Use (CHMP) concluded the benefits of Talmanco outweigh the identified risks, similar to the reference product Adcirca.
  • Safety and usage information include precautions and measures to ensure the effective and safe application of Talmanco, with recommendations incorporated into the product’s summary of characteristics and package leaflet.
  • The marketing authorization for Talmanco was granted on January 9, 2017, under the former name “Tadalafil Generics,” with a subsequent name change to Talmanco effective March 1, 2017.

What may be missing from the usual framing

The EMA report, as a regulatory public assessment, focuses on the technical and clinical equivalence of Talmanco to an already authorized medicine. It does not provide independent clinical trial data specifically on Talmanco, since generic medicines are approved based on their bioequivalence rather than novel efficacy trials.

There is no detailed discussion on long-term clinical outcomes or post-marketing surveillance data specifically for Talmanco, limiting insight into its real-world efficacy and rare adverse effects. The document also does not address issues such as patient adherence, accessibility, or cost implications related to generic entry.

Economic incentives or market dynamics that might influence generic availability, such as pricing strategies or patent considerations, are not mentioned.

Competing evidence or uncertainty

While Talmanco is deemed bioequivalent to Adcirca and thus expected to have the same clinical effect, direct head-to-head clinical trials comparing Talmanco with Adcirca in PAH patients are not reported in the source.

Bioequivalence studies typically measure plasma drug concentration profiles in healthy volunteers, which may not capture all differences in efficacy or safety in diverse patient populations with PAH and comorbidities.

The source does not mention any pharmacovigilance or comparative effectiveness studies post-authorization, leaving some uncertainty about variability in patient response or rare adverse reactions specific to Talmanco.

Additionally, the effects of Talmanco in patients with severe kidney or liver disease remain unclear as it is not recommended for these populations, without further explanation on risks involved.

Why it matters

PAH is a serious disease that significantly limits patient quality of life through impaired exercise capacity and progression to heart failure. Effective management with drugs like tadalafil can improve outcomes and symptom control.

The approval of a generic tadalafil product like Talmanco potentially expands access by providing a lower-cost alternative to the branded medicine Adcirca, encouraging more affordable treatment options across the EU.

Bioequivalence-based approval expedites the availability of generic medicines but requires ongoing vigilance to confirm that therapeutic equivalence translates into real-world benefit without unforeseen safety concerns.

The information is important for healthcare professionals and patients for informed prescribing and use, particularly regarding dosing adjustments in renal or hepatic impairment.

What to verify next

  • Further clinical data or real-world studies comparing safety and effectiveness outcomes between Talmanco and Adcirca in patients with PAH.
  • Post-marketing surveillance reports documenting adverse event patterns specific to Talmanco.
  • Economic analyses regarding the impact of Talmanco’s availability on treatment costs and healthcare access.
  • Comprehensive guidance on use in patients with severe kidney or liver conditions to better understand contraindications and risk management.

Readers are encouraged to consult the original European Medicines Agency public assessment report for Talmanco to review the full scope of regulatory evaluation and product information.

Source & verification

Primary source: What's new · November 17, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EudraGMDP database

What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…